Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 30, 2008 (Second Quarter of Fiscal Year 2008)
Business Overview: The Company operates through two primary segments: CooperVision (CVI), which develops and markets contact lenses, and CooperSurgical (CSI), which manufactures medical devices and surgical instruments for gynecologists and obstetricians.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Apr 30, 2008 |
Three Months Ended Apr 30, 2007 |
Six Months Ended Apr 30, 2008 |
Six Months Ended Apr 30, 2007 |
|---|---|---|---|---|
| Net Sales | $263,451 | $225,535 | $508,484 | $444,955 |
| Gross Profit | $150,008 | $126,456 | $292,890 | $256,368 |
| Gross Margin | 57% | 56% | 58% | 58% |
| Operating Income | $28,466 | $10,531 | $48,417 | $26,293 |
| Net Income | $11,241 | $(527) | $18,118 | $4,821 |
| Diluted EPS | $0.25 | $(0.01) | $0.40 | $0.11 |
| Cash from Operations (6mo) | $11,492 (2008) vs $48,434 (2007) | |||
| Total Debt | $941.0 million (Apr 30, 2008) | |||
| Cash & Equivalents | $1.9 million (Apr 30, 2008) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17% in the quarter and 14% year-to-date, driven by volume growth in both segments. CVI sales grew 18% (quarter) and 15% (YTD), while CSI sales grew 11% in both periods.
- Profitability Surge: Operating income increased 170% in the quarter and 84% year-to-date. This improvement was driven by higher sales volume, improved manufacturing efficiencies, and a significant reduction in restructuring costs compared to the prior year.
- Restructuring Costs: Restructuring costs decreased significantly to $0.5 million in the quarter (from $2.8 million) and $1.3 million YTD (from $4.7 million), reflecting the maturation of the Ocular Sciences integration plan.
- Cash Flow Decline: Operating cash flow decreased to $11.5 million for the six-month period (from $48.4 million) primarily due to increased inventory build-up to support new product launches and the reduction of accrued liabilities.
- Debt Levels: Total debt increased to $941.0 million from $876.6 million at the end of the prior fiscal year, reflecting increased long-term borrowings used for capital expenditures.
Guidance, Outlook, and Risks
- Product Outlook: Management expects continued growth in the contact lens market, particularly in specialty lenses (toric, multifocal) and silicone hydrogel products (Biofinity and Avaira). CVI anticipates launching a silicone hydrogel toric lens in the first half of 2009.
- Capital Expenditures: Fiscal 2008 capital expenditures are expected to be $160 million to $170 million, primarily for expanding silicone hydrogel manufacturing capacity and IT systems. Fiscal 2009 CapEx is projected to decrease to $125 million to $140 million.
- Convertible Debt Put Option: Holders of 2.625% Convertible Senior Debentures have a one-day right to surrender securities for repurchase on July 1, 2008. If fully exercised, the Company intends to fund the approximately $115 million repurchase via its revolving credit facility.
- Legal Contingencies: The Company is defending against a securities class action lawsuit regarding the Ocular merger and financial projections, as well as a patent infringement lawsuit filed by Bausch & Lomb regarding Biomedics toric lenses. Management believes the patent suit is without merit.
- Risk Factors: Key risks include delays in new product launches, regulatory approval delays, supply chain disruptions for silicone hydrogel components, and foreign currency exchange rate fluctuations.
Investor Verification Checklist
- Inventory Levels: Verify the recoverability of the increased inventory balance ($293.4 million) built to support new product launches.
- Convertible Debt Repurchase: Monitor the July 1, 2008, put option exercise rate for the convertible debentures and the impact on liquidity.
- Legal Proceedings: Track developments in the In re Cooper Companies, Inc. Securities Litigation and the Bausch & Lomb patent infringement case.
- Operating Cash Flow: Assess whether the decline in operating cash flow is temporary due to inventory build-up or indicative of working capital inefficiencies.
- Effective Tax Rate: Review the impact of geographic income mix on the effective tax rate, which increased to 28.8% for the six-month period.